Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADIL Adial Pharmaceuticals

Market Closed 11-01 16:00:00 EDT

1.01

+0.01

+1.00%

盘后1.00

-0.01-0.96%

17:56 EDT

High1.02	Low0.9770	Vol37.66K
Open0.9990	D1 Closing1.00	Amplitude4.30%
Mkt Cap6.47M	Tradable Cap6.35M	Total Shares6.41M
T/O37.60K	T/O Rate0.60%	Tradable Shares6.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ADIL","market":"US","secType":"STK","nameCN":"Adial Pharmaceuticals","latestPrice":1.01,"timestamp":1730491200000,"preClose":1,"halted":0,"volume":37662,"hourTrading":{"tag":"盘后","latestPrice":1.0003,"preClose":1.01,"latestTime":"17:56 EDT","volume":630,"amount":632.3109,"timestamp":1730498166740},"delay":0,"floatShares":6290530,"shares":6405781,"eps":-4.599432,"marketStatus":"Market Closed","change":0.01,"latestTime":"11-01 16:00:00 EDT","open":0.999,"high":1.02,"low":0.977,"amount":37596.7995456,"amplitude":0.043,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.599432,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730710800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1532664000000,"exchange":"NASDAQ","adjPreClose":1,"preHourTrading":{"tag":"盘前","latestPrice":0.9999,"preClose":1,"latestTime":"08:19 EDT","volume":10,"amount":9.999,"timestamp":1730463585798},"postHourTrading":{"tag":"盘后","latestPrice":1.0003,"preClose":1.01,"latestTime":"17:56 EDT","volume":630,"amount":632.3109,"timestamp":1730498166740},"volumeRatio":0.3921352225282614,"impliedVol":3.592,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ADIL/tweets","defaultTab":"tweets","newsList":[{"id":"2477587874","title":"Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2477587874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477587874?lang=en_us&edition=fundamental","pubTime":"2024-10-23 21:00","pubTimestamp":1729688400,"startTime":"0","endTime":"0","summary":"GLEN ALLEN, Va., Oct.  23, 2024  (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/23/2967823/0/en/Adial-Pharmaceuticals-to-Present-at-the-2024-ThinkEquity-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4125","BK4007","WRD","AUD"],"gpt_icon":0},{"id":"2476489887","title":"Adial Pharmaceuticals Gets US Patent Allowance for Expanded Genotypes in Addiction Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2476489887","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476489887?lang=en_us&edition=fundamental","pubTime":"2024-10-18 02:01","pubTimestamp":1729188075,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals  said Thursday it has received a notice of allowance from the US Patent and Trademark Office for a new patent covering additional genotype combinations identified through its genetic diagnostic tool.The company said that once issued, the patent will expand its intellectual property protection around AD04, its lead investigational drug that aims to treat alcohol use disorder.Adial shares were down more than 6% in recent trading.Price: 0.97, Change: -0.07, Percent Change: -6.31","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADIL","BK4007"],"gpt_icon":0},{"id":"2476210801","title":"Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2476210801","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476210801?lang=en_us&edition=fundamental","pubTime":"2024-10-17 21:00","pubTimestamp":1729170000,"startTime":"0","endTime":"0","summary":"Expands patent estate covering Adial’s unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence. GLEN ALLEN, Va., Oct. 17, 2024  -- Adial Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent.The patent, once issued, will expand Adial's intellectual property protection around its lead investigational drug, AD04, which is designed to treat alcohol use disorder . The new patent covers additional genotype combinations identified through the Company’s proprietary genetic diagnostic tool, further enhancing the precision medicine approach of AD04.This communication contains certain \"forward-looking statements\" within the meaning of the U.S. federal securities laws. Such state","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8DtLazjanj2E0zoEXN813A--~B/aD0xMjM7dz0yODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7788d45e6599b04724e37cb707974212","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8DtLazjanj2E0zoEXN813A--~B/aD0xMjM7dz0yODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7788d45e6599b04724e37cb707974212"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adial-pharmaceuticals-receives-notice-allowance-130000338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADIL","GENE","BK4125","BK4121","BK4007","AUD"],"gpt_icon":0},{"id":"2476126536","title":"EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2476126536","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476126536?lang=en_us&edition=fundamental","pubTime":"2024-10-17 20:30","pubTimestamp":1729168253,"startTime":"0","endTime":"0","summary":"On Thursday, Adial Pharmaceuticals, Inc.  announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent.The patent, once issued, will expand Adial’s intellectual property protection around its lead investigational drug, AD04, which is designed to treat alcohol use disorder .Also Read: EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder.AD04 is the company’s lead investigational new drug product, a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder  in heavy drinking patients and was recently investigated in the ONWARD Phase 3 trial for the potential treatment of AUD in subjects with certain target genotypes identified using the company’s proprietary companion diagnostic genetic test.In April, Adial Pharmaceuticals announced a new US patent, expanding Adial’s intellectual property protection and covering the combination","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Re6..uIYvTd3gxZrgPI6NQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/c694728b6fc0d7463dd3eac613574662","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Re6..uIYvTd3gxZrgPI6NQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/c694728b6fc0d7463dd3eac613574662"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-adial-pharmaceuticals-secures-additional-123053502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AUD","ADIL","BK4007","BK4125"],"gpt_icon":0},{"id":"2475415502","title":"Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2475415502","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475415502?lang=en_us&edition=fundamental","pubTime":"2024-10-15 21:00","pubTimestamp":1728997200,"startTime":"0","endTime":"0","summary":"AD04 Program Aligned with NIAAA's New Inclusion of Non-Abstinence Solutions, Validating Commercial and Government Market Potential. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder  in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. ONWARD showed promising resu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8DtLazjanj2E0zoEXN813A--~B/aD0xMjM7dz0yODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7788d45e6599b04724e37cb707974212","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8DtLazjanj2E0zoEXN813A--~B/aD0xMjM7dz0yODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7788d45e6599b04724e37cb707974212"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adial-pharmaceuticals-commends-national-institute-130000170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AUD","ADIL","BK4125","BK4007","NHLD"],"gpt_icon":0},{"id":"2469676366","title":"Maxim Group Keeps Their Hold Rating on Adial Pharmaceuticals (ADIL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2469676366","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469676366?lang=en_us&edition=fundamental","pubTime":"2024-09-21 00:26","pubTimestamp":1726849561,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy maintained a Hold rating on Adial Pharmaceuticals (ADIL – Research Report) yesterday. The company’s shares opene...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-hold-rating-on-adial-pharmaceuticals-adil-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-hold-rating-on-adial-pharmaceuticals-adil-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADIL"],"gpt_icon":0},{"id":"2468576197","title":"Adial Pharmaceuticals : Topline Results Are Expected to Be Announced During Q4 of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2468576197","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468576197?lang=en_us&edition=fundamental","pubTime":"2024-09-19 20:30","pubTimestamp":1726749000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nTUA5JWH8G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADIL","BK4007"],"gpt_icon":0},{"id":"2468457617","title":"Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of Ad04 for the Treatment of Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2468457617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468457617?lang=en_us&edition=fundamental","pubTime":"2024-09-19 20:30","pubTimestamp":1726749000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nTUA5JWH8G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADIL","BK4007"],"gpt_icon":0},{"id":"2468576735","title":"Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2468576735","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468576735?lang=en_us&edition=fundamental","pubTime":"2024-09-19 20:30","pubTimestamp":1726749000,"startTime":"0","endTime":"0","summary":"Topline results expected in fourth quarter of 2024. GLEN ALLEN, Va., Sept. 19, 2024  -- Adial Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced database lock for the pharmacokinetics study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder  in heavy drinking patients . Topline results are expected to be announced during the fourth quarter of 2024.This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, pe","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8DtLazjanj2E0zoEXN813A--~B/aD0xMjM7dz0yODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7788d45e6599b04724e37cb707974212","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8DtLazjanj2E0zoEXN813A--~B/aD0xMjM7dz0yODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7788d45e6599b04724e37cb707974212"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adial-pharmaceuticals-announces-database-lock-123000012.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AUD","ADIL","BK4125","BK4007"],"gpt_icon":0},{"id":"2459405943","title":"Maxim Group Sticks to Its Hold Rating for Adial Pharmaceuticals (ADIL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2459405943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459405943?lang=en_us&edition=fundamental","pubTime":"2024-08-16 01:35","pubTimestamp":1723743317,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Adial Pharmaceuticals (ADIL – Research Report). The com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-its-hold-rating-for-adial-pharmaceuticals-adil-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-its-hold-rating-for-adial-pharmaceuticals-adil-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADIL"],"gpt_icon":0},{"id":"2459416253","title":"Adial Pharmaceuticals reports Q2 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2459416253","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459416253?lang=en_us&edition=fundamental","pubTime":"2024-08-15 15:37","pubTimestamp":1723707427,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals press release : Q2 net loss was $2.5 million for the three months ended June 30, 2024, compared to a net income of $1.1 million for the three months ended June 30, 2023. Cash and cash equivalents were $3.3 million as of June 30, 2024, compared to $2.8 million as of December 31, 2023.  Including the proceeds from at-the-market facility, the Company believes that its existing cash and cash equivalents will fund its operating expenses into the second half of 2025 based on current commitments and development plans.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4140164-adial-pharmaceuticals-reports-q2-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2459017587","title":"Adial Pharmaceuticals Q2 EPS $(0.59) Up From $(1.33) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2459017587","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459017587?lang=en_us&edition=fundamental","pubTime":"2024-08-14 20:33","pubTimestamp":1723638808,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(0.59) per share. This is a 55.64 percent increase over losses of $(1.33) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40365294/adial-pharmaceuticals-q2-eps-0-59-up-from-1-33-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Adial Pharmaceuticals Q2 EPS $(0.59) Up From $(1.33) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL"],"gpt_icon":0},{"id":"2459173123","title":"Adial Pharmaceuticals Inc: Believes Existing Cash & Cash Equivalents to Fund Its Operating Expenses Into H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2459173123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459173123?lang=en_us&edition=fundamental","pubTime":"2024-08-14 20:30","pubTimestamp":1723638602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240814:nTUA1X7MZ6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ADIL"],"gpt_icon":0},{"id":"2459417344","title":"Adial Pharmaceuticals Q2 Net Income USD -2.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2459417344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459417344?lang=en_us&edition=fundamental","pubTime":"2024-08-14 20:30","pubTimestamp":1723638601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240814:nPLX0C44D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADIL","USD","BK4007"],"gpt_icon":0},{"id":"2459818345","title":"Adial Signs Deal With Boudicca to Advance Regulatory Strategy for Companion Diagnostic Genetic Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2459818345","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459818345?lang=en_us&edition=fundamental","pubTime":"2024-08-13 23:20","pubTimestamp":1723562412,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4121","ADIL","GENE","BK4007"],"gpt_icon":0},{"id":"2459518395","title":"Adial Signs Deal With Boudicca to Advance Regulatory Strategy for Companion Diagnostic Genetic Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2459518395","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459518395?lang=en_us&edition=fundamental","pubTime":"2024-08-13 23:20","pubTimestamp":1723562412,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals  said Tuesday it is partnering with Boudicca Dx to progress regulatory strategy for its companion diagnostic genetic test for its lead investigational asset, AD04, a therapeutic agent for the treatment of Alcohol Use Disorder.Boudicca will help ensure it is validated both technically and clinically per the US Food and Administration guidelines, Adial said.The company said its companion diagnostic is intended to accompany AD04 in identifying potential patients, including recruitment for its planned phase 3 program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADIL","GENE","BK4007","BK4121"],"gpt_icon":0},{"id":"2459903170","title":"Adial Pharmaceuticals Signs Agreement With Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for Ad04","url":"https://stock-news.laohu8.com/highlight/detail?id=2459903170","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459903170?lang=en_us&edition=fundamental","pubTime":"2024-08-13 21:00","pubTimestamp":1723554003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUA7D1QJ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADIL","BK4121","BK4007","GENE"],"gpt_icon":0},{"id":"2459903784","title":"Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04","url":"https://stock-news.laohu8.com/highlight/detail?id=2459903784","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459903784?lang=en_us&edition=fundamental","pubTime":"2024-08-13 21:00","pubTimestamp":1723554000,"startTime":"0","endTime":"0","summary":"Boudicca will support and advise Adial on its companion diagnostic genetic test to ensure compliance with FDA guidelinesGLEN ALLEN, Va., Aug.  13, 2024  (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/13/2929261/26135/en/Adial-Pharmaceuticals-Signs-Agreement-with-Boudicca-Dx-to-Advance-Regulatory-Strategy-for-Companion-Diagnostic-Genetic-Test-for-AD04.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4125","BK4007","AUD","GENE","BK4121","ADIL"],"gpt_icon":0},{"id":"2459084989","title":"EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2459084989","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459084989?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:30","pubTimestamp":1723552228,"startTime":"0","endTime":"0","summary":"On Tuesday, Adial Pharmaceuticals Inc.  announced a collaboration with Boudicca Dx, LLC, a global precision medicine testing accelerator.Under the agreement, Boudicca will support Adial in advancing its technical and regulatory strategy for the company’s companion diagnostic genetic test to ensure it is validated technically and clinically per FDA guidelines as part of Adial’s regulatory strategy for its lead investigational asset, AD04.Also Read: EXCLUSIVE: Adial Pharmaceuticals’ Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4.AD04 is a genetically-targeted, serotonin-3 receptor antagonist therapeutic agent for Alcohol Use Disorder .Adial’s companion diagnostic is intended to assist AD04 in identifying potential patients and recruiting for the planned Phase 3 program.This article EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder originally ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qrHm0iRtvCyH.LW6URUcCA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/0ec2b6f8f15cadf0cb47a83fa188dac3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qrHm0iRtvCyH.LW6URUcCA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/0ec2b6f8f15cadf0cb47a83fa188dac3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-adial-pharmaceuticals-advances-regulatory-123028776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","GENE","AUD","ADIL","BK4125","BK4007"],"gpt_icon":0},{"id":"2457877846","title":"Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of Ad04 for the Treatment of Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2457877846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457877846?lang=en_us&edition=fundamental","pubTime":"2024-08-07 21:00","pubTimestamp":1723035602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240807:nTUA6TLNML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ADIL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adialpharma.com","stockEarnings":[{"period":"1week","weight":-0.0818},{"period":"1month","weight":0.0626},{"period":"3month","weight":0},{"period":"6month","weight":-0.4059},{"period":"1year","weight":-0.5702},{"period":"ytd","weight":-0.457}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0716},{"period":"6month","weight":0.1169},{"period":"1year","weight":0.3257},{"period":"ytd","weight":0.2014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.11348},{"month":2,"riseRate":0.333333,"avgChangeRate":0.054105},{"month":3,"riseRate":0,"avgChangeRate":-0.126633},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.03704},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.095363},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.091774},{"month":7,"riseRate":0.5,"avgChangeRate":0.019629},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.065704},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.033423},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.173095},{"month":11,"riseRate":0.571429,"avgChangeRate":0.175324},{"month":12,"riseRate":0.333333,"avgChangeRate":0.057024}],"exchange":"NASDAQ","name":"Adial Pharmaceuticals","nameEN":"Adial Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adial Pharmaceuticals(ADIL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adial Pharmaceuticals,ADIL,Adial Pharmaceuticals股票,Adial Pharmaceuticals股票老虎,Adial Pharmaceuticals股票老虎国际,Adial Pharmaceuticals行情,Adial Pharmaceuticals股票行情,Adial Pharmaceuticals股价,Adial Pharmaceuticals股市,Adial Pharmaceuticals股票价格,Adial Pharmaceuticals股票交易,Adial Pharmaceuticals股票购买,Adial Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adial Pharmaceuticals(ADIL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction